Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Arrowhead Pharma
(NQ:
ARWR
)
23.98
+1.07 (+4.67%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Arrowhead Pharma
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1/2 Study of ARO-DUX4 for Facioscapulohumeral Muscular Dystrophy
July 17, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
July 06, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Expert Ratings for Arrowhead Pharma
June 30, 2023
Via
Benzinga
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1 Study of ARO-SOD1
June 27, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Where Arrowhead Pharma Stands With Analysts
May 24, 2023
Via
Benzinga
The Latest Analyst Ratings for Arrowhead Pharma
May 03, 2023
Via
Benzinga
Is Arrowhead Pharmaceuticals a Buy Now?
April 16, 2023
The clinical-stage drug developer is attracting a lot of positive attention from investment bank analysts.
Via
The Motley Fool
Arrowhead Presents Updated Data from Phase 2 SEQUOIA Study of Investigational RNAi Therapy Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Liver Disease
June 24, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Eli Lilly Just Lent Its Big Pharma Cachet To Verve's Nascent Gene-Editing Program For $60 Million
June 15, 2023
Eli Lilly inked a deal worth $60 million to get in on a gene-editing drug for elevated lipoprotein A.
Via
Investor's Business Daily
Arrowhead Pharmaceuticals to Participate in Upcoming June 2023 Conferences
June 06, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Expert Ratings for Arrowhead Pharma
April 12, 2023
Via
Benzinga
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
June 02, 2023
Big Pharma is facing a patent cliff that could siphon off billions in revenue.
Via
Investor's Business Daily
Arrowhead Hosts R&D Day Highlighting Its Pipeline of RNAi Therapeutics
June 01, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead CEO Christopher Anzalone Addresses The 'Really Important Event' In Lung Disease
June 01, 2023
Arrowhead CEO Christopher Anzalone discusses expectations for ARO-RAGE in lung disease.
Via
Investor's Business Daily
What Arrowhead Pharmaceutical's Interim Data Reveals About A RNAi Therapeutic For Rare Cholesterol Disorder
May 23, 2023
Via
Benzinga
Arrowhead Presents Interim Data from ARO-ANG3 Phase 2 GATEWAY Study in Patients with HoFH
May 23, 2023
From
Arrowhead Pharmaceuticals Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Completes Enrollment of Phase 3 PALISADE Clinical Trial Evaluating ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome
May 16, 2023
From
Arrowhead Pharmaceuticals Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Participate in Upcoming Conferences
May 15, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 12, 2023
May 12, 2023
Via
Benzinga
Arrowhead Pharmaceuticals Reports Fiscal 2023 Second Quarter Results
May 02, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Why GE HealthCare Technologies Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
April 25, 2023
Gainers
Via
Benzinga
Why Shares of Arrowhead Pharmaceuticals Are Up Tuesday
April 25, 2023
The clinical-stage biotech announced promising news regarding a potential therapy for inflammatory pulmonary diseases.
Via
The Motley Fool
Arrowhead Pharmaceuticals Reveals Data From Healthy Volunteers For Its Asthma Hopeful, Stock Soars
April 25, 2023
Via
Benzinga
Xerox, Hubbell, Spotify And Other Big Stocks Moving Higher On Tuesday
April 25, 2023
U.S. stocks traded lower, with the Nasdaq Composite dropping around 100 points on Tuesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
April 25, 2023
Via
Benzinga
Arrowhead Pharmaceuticals’ Proprietary Pulmonary TRiM™ Platform Achieves High Levels of Target Gene Knockdown and Long Duration of Effect
April 25, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Second Quarter Results
April 18, 2023
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) Making Surprising Moves in Thursday Session
April 13, 2023
Via
Investor Brand Network
Analyst Upgrades Arrowhead Pharma Citing 'Attractive Risk/Reward'
April 12, 2023
SVB Securities upgraded Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) to Outperform from Market Perform on attractive risk-reward following shares' underperformance relative to larger cap oligo therapy...
Via
Benzinga
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) Highlighted for Surprising Price Action
April 12, 2023
Via
Investor Brand Network
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.